[7] In August 2011, SIGA Technologies was awarded a $7.7 million grant from the National Institutes of Health (NIH) to develop an antiviral drug for treating and preventing Lassa fever and others of arenavirus origin.

[12] In May 2018, a US Food and Drug Administration (FDA) advisory committee decided that the benefits of SIGA's small molecule antiviral treatment, Tpoxx, outweigh its potential risks.

[18] In January 2022, the European Medicines Agency approved oral tecovirimat for smallpox, monkeypox, cowpox and vaccinia complications in adults and children with a body weight of at least 13kg.

[19] The Centers for Disease Control and Prevention and the FDA have relaxed regulations to make it easier for doctors in the United States to prescribe Tpoxx to treat people with monkeypox.

[24] SIGA's products include tecovirimat, sold under the brand name Tpoxx, the first drug approved by the FDA to treat adults and children for smallpox.